Portal de Periódicos da CAPES

Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease

2021; American Medical Association; Volume: 78; Issue: 10 Linguagem: Inglês

10.1001/jamaneurol.2021.1312

2168-6157

Trina Mitchell, Stéphane Lehericy, Shannon Chiu, Antonio P. Strafella, A. Jon Stoessl, David E. Vaillancourt,

Advanced Neuroimaging Techniques and Applications

Imaging biomarkers in Parkinson disease (PD) are increasingly important for monitoring progression in clinical trials and also have the potential to improve clinical care and management. This Review addresses a critical need to make clear the temporal relevance for diagnostic and progression imaging biomarkers to be used by clinicians and researchers over the clinical course of PD. Magnetic resonance imaging (diffusion imaging, neuromelanin-sensitive imaging, iron-sensitive imaging, T1-weighted imaging), positron emission tomography/single-photon emission computed tomography dopaminergic, serotonergic, and cholinergic imaging as well as metabolic and cerebral blood flow network neuroimaging biomarkers in the preclinical, prodromal, early, and moderate to late stages are characterized.